Literature DB >> 4025352

Potential drug interactions in surgical patients.

C W Durrence, J T DiPiro, J R May, R R Nesbit, J F Sisley, J W Cooper.   

Abstract

The incidence and frequency of potentially serious drug interactions were evaluated in hospitalized surgical patients. Drug profiles of patients on the general surgical service of a tertiary-care teaching hospital were retrospectively reviewed for two six-month periods to determine how often drugs that are known for major interactions were prescribed concurrently. Interactions were studied that were relatively well documented and potentially harmful to the patients. A total of 1825 patient profiles were reviewed (21,888 patient days). At least one potential drug interaction was found in 17% of the patients. Interactions were found to occur at the rate of 1 for every 59 patient days. Digoxin and cimetidine were the potential interacting drugs in almost 90% of the cases. Hospitalized surgical patients require close monitoring because they frequently receive potentially interacting drugs.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4025352

Source DB:  PubMed          Journal:  Am J Hosp Pharm        ISSN: 0002-9289


  3 in total

1.  Drug-drug interactions among recently hospitalised patients--frequent but mostly clinically insignificant.

Authors:  Bente Glintborg; Stig Ejdrup Andersen; Kim Dalhoff
Journal:  Eur J Clin Pharmacol       Date:  2005-10-19       Impact factor: 2.953

2.  Impact of educational intervention on the pattern and incidence of potential drug-drug interactions in Nepal.

Authors:  Durga Bista; Archana Saha; Pranaya Mishra; Subish Palaian; Pathiyil R Shankar
Journal:  Pharm Pract (Granada)       Date:  2009-03-15

3.  Medication Interaction and Physicians' Compliance Assessment through Medication Reconciliation Forms in a University Affiliated Hospital.

Authors:  Mohammad Mehdi Talebi; Aida Sefidani Forough; Parsa Riazi Esfahani; Raha Eskandari; Roodabeh Haghgoo; Fanak Fahimi
Journal:  Iran J Pharm Res       Date:  2018       Impact factor: 1.696

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.